Advanced Therapy Medicinal Products CDMO Market (By Product: Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold); By Phase: Phase I, Phase II, Phase III, Phase IV; By Indication: Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Haematology, Gastroenterology) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Advanced Therapy Medicinal Products CDMO Market, By Product

7.1.  Advanced Therapy Medicinal Products CDMO Market, by Product, 2021-2030

7.1.1.    Gene Therapy

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Cell Therapy

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Tissue Engineered

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Others (Combined ATMPs, for example biodegradable matric or scaffold)

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Advanced Therapy Medicinal Products CDMO Market, By Phase

8.1.  Advanced Therapy Medicinal Products CDMO Market, by Phase, 2021-2030

8.1.1.    Phase I

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Phase II

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Phase III

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Phase IV

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Advanced Therapy Medicinal Products CDMO Market, By Indication

9.1.  Advanced Therapy Medicinal Products CDMO Market, by Indication, 2021-2030

9.1.1.    Oncology

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Cardiology

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Central Nervous System

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Musculoskeletal

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    Infectious Disease

9.1.5.1.        Market Revenue and Forecast (2017-2030)

9.1.6.    Dermatology

9.1.6.1.        Market Revenue and Forecast (2017-2030)

9.1.7.    Endocrine, Metabolic, Genetic

9.1.7.1.        Market Revenue and Forecast (2017-2030)

9.1.8.    Immunology & Inflammation

9.1.8.1.        Market Revenue and Forecast (2017-2030)

9.1.9.    Ophthalmology

9.1.9.1.        Market Revenue and Forecast (2017-2030)

9.1.10.  Haematology

9.1.10.1.      Market Revenue and Forecast (2017-2030)

9.1.11.  Gastroenterology

9.1.11.1.      Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Advanced Therapy Medicinal Products CDMO Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Product (2017-2030)

10.1.2.  Market Revenue and Forecast, by Phase (2017-2030)

10.1.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Product (2017-2030)

10.2.2.  Market Revenue and Forecast, by Phase (2017-2030)

10.2.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Product (2017-2030)

10.3.2.  Market Revenue and Forecast, by Phase (2017-2030)

10.3.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Product (2017-2030)

10.4.2.  Market Revenue and Forecast, by Phase (2017-2030)

10.4.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Product (2017-2030)

10.5.2.  Market Revenue and Forecast, by Phase (2017-2030)

10.5.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

Chapter 11.  Company Profiles

11.1.              Company 1

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Company 2

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Company 3

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Company 4

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Company 5

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Company 6

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Company 7

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Company 8

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Company 9

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Company 10

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms

Report Detail

Proceed To Buy

USD 3500
USD 7000